Cardiovascular Risk Profile: Even without significant obesity, patients with established heart disease, prior stroke, or multiple cardiac risk factors benefit from the cardiovascular protective effects beyond weight loss alone
Behavioral Therapy: Changing ones mindset and habits is key to sustaining weight loss
Quantitation of therapy induced cytoreduction in acute myeloblastic leukemias (AML): A comparison of two induction regiments
The cycle planning guide discusses how to structure protocols for different goals
For example, some sources suggest starting at ~100 mcg for peptides like DSIP, and then adjust only if needed

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Novo Nordisk Wins EU Approval for First Oral GLP-1 Weight-Loss Drug Wegovy Bengaluru : Novo Nordisk said on Wednesday the European Commission approved its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, making it the first oral GLP-1 weight-loss treatment cleared for use across the European Union
